MediQstar

Founded in 2023, MediQstar is a medical technology company headquartered in Seoul, South Korea, with an additional office in Gwangju. The company is developing solutions for tuberculosis diagnosis and is led by CEO Yoo Seung-jae.

MediQstar operates as an Artificial Intelligence Contract Research Organization (AI CRO), employing generative AI and multimodal data to create virtual human models for clinical trials. This biosimulation technology aims to significantly reduce the time and costs associated with traditional clinical trial processes. The company's AI CRO model can simulate trials in approximately one month with no human participants, a substantial decrease from the typical eight years and 5,000+ participants required for conventional methods.

The firm's business model is centered on providing specialized AI CRO services, including AI diagnostic kits and bio-AI analysis for new drugs. By leveraging a medical large language model (med-MLLM) and a database of patient multimodal data, the company can generate virtual test subjects to improve the efficiency of clinical trials and assist in the precise selection of new drug candidates. The company is currently generating revenue and in July 2025, it secured Series A funding from investors including HB Investment, Pathfinder H, Genaxis (Korea), and the Tech Incubator Program for Startup (TIPS).

Keywords: AI CRO, clinical trial simulation, biosimulation, generative AI, tuberculosis diagnosis, medical technology, multimodal data, virtual clinical trials, med-MLLM, diagnostic equipment, HealthTech, AI diagnostics, new drug development, clinical research, AI medical model, digital health, pharmaceutical technology, life sciences, medical AI, virtual test subjects